Section 32

Venture Capital Active United States
Last updated 2026-06-18
Portfolio
2
in our dataset
Rounds participated
3
Rounds led
0
Rounds' value
$147.0M
total disclosed, rounds participated
Stages
—

Portfolio · 2

Nucleai
Spatial Biology Software Platform for Precision Medicine
2 rounds $47.0M committed Latest: 2024-04
C2i Genomics
Whole-genome Cancer Treatment Intelligence Platform
1 round $100.0M committed Latest: 2021-04

Investment activity

1 portfolio exit on record.

Portfolio by sector

Health Tech & Life Sciences2

Q&A

What is Section 32's primary investment focus by sector?
Section 32 primarily focuses its investments within the Health Tech & Life Sciences sector, with all of its portfolio companies and exits concentrated in this area.
Can you name a notable exit for Section 32?
In January 2024, Section 32 saw an exit with the acquisition of C2i Genomics by Veracyte for $95 million.
Which funding stages does Section 32 typically participate in?
Section 32 has participated in B Round funding stages, including both initial and follow-on investments.
What is one of Section 32's active portfolio companies?
Nucleai, a Spatial Biology Software Platform for Precision Medicine, is one of Section 32's active portfolio companies. It raised a $60.5 million Series B round.
When was Section 32 founded?
Section 32 was founded in 2021.
What is the typical investment range for Section 32?
Section 32's investment range is between $14 million and $100 million.